PPP March

1. Traumatic Brain Injury
Complex problem – Creative solution
March 2021
©

2. Introduction to the
TBI problem

3. •
•
•
•
•
• The Need: Rapid detection for
undiagnosed head injuries

4. 48 %
17 %
13 %
8 %
14 % Falls
Assault
Motor vehicle
accidents Being struck by or
against an object
Leading Causes of TBI
Other or unknown
cause
Blasts and explosions,
Firearms, Diving, Medical

5. TBI – A Global Problem
•
•
•
•
•
New cases each year
90% of cases are mild
traumatic brain injuries

6. Our Solution for Diagnostics
™

7. Easy-to-read

8. A Diagnostic Test
Based on a New Biomarker

9. Why is the kit needed?
•
•
•

10. • biomarker
test
•
•

11. Preclinical results indicated the existence of
unique biomarkers following a head injury
Control animals (no injury)
Head injured animals
Biomarker elevation after injury
(fluoresent detection)
Intensity
increase
(2
parallel
spots/biomarker)

12. Clinical trials
24
16
29
12
12
•
•
•
•
Completed

13. 30
30
Binding analysis
Biomarker detection
Mass spectrometry
Glycome analysis
3D-structure
2020-Q2 2021-Q2

14. Clinical Trials – Conclusions
•
•
•
• Medicortex reached a significant milestone

15. A case study – Testimonial
•
•
•
•
•
•
•

16. Biomarker results

17. The case study – second MRI
MRI scanning was repeated after the biomarker results
•
•

18. From an Idea to the Product

Clinical evaluation of the final product


19. Financial and Development Milestones
PHASE
PRE-
CLINICAL
STUDIES
FIRST CLINICAL
STUDY
SECOND
CLINICAL STUDY
PEDIATRIC
CLINICAL STUDY
PROTOTYPE
DEVELOPMENT
VALIDATION
AND
APPROVAL
TASKS
™
™
MILESTONES
FUNDING
NEEDED
(M€)*
 1.0  2.5  2.5
STATUS

20. ProbTBI™ Kit advantages
Fast Easy to use
Mobility Patient friendly
No radiation or
contrast agent
exposition
Affordable
Can be sold as
"off the shelf" product
ProbTBI™
Kit

21. Our Clients
Army
paramedics
Hospitals and
emergency rooms
Paramedics First
responders
Sport
teams
Nursing
homes
Insurance
companies
Pharma
companies
Private
people

22. Market Potential
Brain Trauma Monitoring Market Value Estimate (US market alone)

23. Intellectual Property
Position

24. Medicortex' patents for the
biomarker and diagnostics
1. Prognostic and Diagnostic Glycan-based Biomarkers of Brain
Damage
•
•
2. Non-invasive brain injury diagnostic device
•
•
3. Device and method for detecting of brain injury in a subject
•
4. A method for determining a lectin-binding glycan indicative to
traumatic brain injury
•

25. Medicortex' patents for the
drug development
Multivalent compounds for use in the treatment and prevention
of brain damage
•
•
•
•
Conjugates and conjugates for use in preventing or treating of
brain damage and neurodegenerative diseases
•

26. Public and Private
Financing

27. Equity up to now
•
•
New equity & Financing
•
•
Subsidies
•
•

28. Total Investment Required
2021–2023
Investment needed for the entire
project 5 M€ it will enable:
•
•
•
•

29. Ownership following an investment
A new investment of 5 M€ will give Investor 32% of the company’s
share equity.
38.4%
25.9%
3.7%
32%
Dr. Adrian Harel
The new
investment (5 M€)
Private Swedish Investor Other Shareholders

30. From 2014–2021 increase in value
0
2
4
6
8
10
12
Valuation
(M€)
Price
per
Share
(€) Value Creation
Valuation (M€) Price per Share
Paediatric Clinical Trial
Prototype development
Q3/2014 Q3/2015 Q2/2016 Q4/2016 Q4/2017 Q4/2018 Q3/2019 Q1/2021
Funding from
Tekes and new
Investors
DoD
funding
Human Clinical
Trials in three
hospitals
First Human Clinical Trial
Positive clinical results
Crowdfunding
Positive
preclinical
results

31. Acquisitions and Buy-Outs 2019–2021
(Some examples)
Transaction Value Approx. (M€)
Target company / Acquired by:

32. Board of Directors
• Adrian Harel
• Mårten Kvist
• Tom Palenius

33. Scientific and Clinical Advisory Board
Heikki Rauvala
Lauri Kangas
Risto O. Roine
Timo Kurki
Antti Kaipia
Markku Tuominen

34. The Team
Adrian Harel Mårten Kvist
Lasse Välimaa Oskar Haavisto
Tomas Ward
Begum Utz
Financial and Legal Services
Marjukka Iitti Iiro Hollmén
PwC
Laboratory Assistant
Venla-Mari Nurmi
Project Manager
Maria Grönman

35. Medicortex
in the Press
2
3
4
5
6
7
1

36. Concussion in sports and Medicortex test
Concussion in army personnel and Medicortex test

37. www.medicortex.fi
Contact:
Dr. Adrian Harel, CEO
adrian.harel@medicortex.fi